ReviewOncoimmunology
HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.
Review in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 98 citations in OpenAlex.
- Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.JNCI cancer spectrum · 2021Trial
- Review
- Tumour immune contexture and immune evasion in sporadic and Lynch syndrome-associated microsatellite unstable colorectal cancers.British journal of cancer · 2026Article
- The aryl hydrocarbon receptor (AHR) drives human leukocyte antigen (HLA)-II expression in human melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- A novel multivariate framework for functional gene networks enrichment analysis.Frontiers in genetics · 2026Article
- Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development.Nature reviews. Immunology · 2026Review
- Cross-scale modeling reveals a TFRC-driven immunosuppressive macrophage niche in cervical cancer.Frontiers in immunology · 2026Article
- Independent and joint effects of lifestyle, human leukocyte antigen polymorphisms on cancer risk: findings from the UK Biobank.Frontiers in immunology · 2026Article
- Distinct transcriptomic features of tumor and stromal cells in direct contact in luminal and triple-negative breast cancers.Exploration of targeted anti-tumor therapy · 2026Article
- Crosstalk between autophagy and apoptosis in initiating antitumor immune responses in human lymphoma cells.Exploration of immunology · 2025Article
- Association of HLA-DRA expression with prognosis and tumor microenvironment in clear cell renal cell carcinoma.Scientific reports · 2025Article
- A pan-cancer atlas of therapeutic T cell targets.bioRxiv : the preprint server for biology · 2025Article
- Associations between HLA-II variation and antibody specificity are predicted by antigen properties.Genome medicine · 2025Article
- Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.Journal for immunotherapy of cancer · 2025Article
- YKL-40 inhibits melanoma progression and metastasis by inducing immune cell infiltration in a mouse model.Scientific reports · 2025Article
- Article
- MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer.PloS one · 2025Article
- Deciphering Antigen Processing Machinery (APM) as One of the Determinants for Responsiveness of Affected Patients towards Anticancer Immunotherapy.Asian Pacific journal of cancer prevention : APJCP · 2024Review
- Trim21-mediated CCT2 ubiquitination suppresses malignant progression and promotes CD4Cell death & disease · 2024Article
- Deciphering CD4Molecular carcinogenesis · 2024Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human leukocyte antigen (HLA) class II antigen-processing machinery (APM) presents to cognate CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.